Runben Biotechnology Co., Ltd. (SHA:603193)
China · Delayed Price · Currency is CNY 20.87
+0.22 (1.07%)
Jun 18, 2026, 11:29 AM CST
Runben Biotechnology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 322.94 | 314.5 | 300.16 | 226.03 | 160.04 | 120.65 |
Depreciation & Amortization | 21.84 | 21.84 | 21.12 | 21.87 | 19.77 | 10.53 |
Other Amortization | 0.35 | 0.35 | 0.15 | 0.11 | - | - |
Loss (Gain) From Sale of Assets | -0.08 | -0.08 | 0.51 | -0.07 | -0.05 | -0 |
Asset Writedown & Restructuring Costs | -0.84 | -0.84 | -3.5 | - | 0 | 0.02 |
Loss (Gain) From Sale of Investments | -19.02 | -19.02 | -3.86 | -0.84 | -2.05 | -1.96 |
Provision & Write-off of Bad Debts | 0.24 | 0.24 | 0.47 | 0.2 | -0.02 | -0 |
Other Operating Activities | 0.28 | -7.91 | -26.05 | -11.5 | 1.62 | 2.71 |
Change in Accounts Receivable | -8.15 | -8.15 | -23.06 | 10.38 | -2.43 | -6.44 |
Change in Inventory | -4.59 | -4.59 | -27.48 | 7.39 | -46.95 | -14.09 |
Change in Accounts Payable | -14.75 | -14.75 | 41.72 | 3.71 | 43.2 | 27.73 |
Change in Other Net Operating Assets | - | - | 0.64 | 1.42 | 0.9 | 2.68 |
Operating Cash Flow | 291.89 | 275.26 | 257.24 | 252.52 | 165.32 | 138.65 |
Operating Cash Flow Growth | 7.88% | 7.00% | 1.87% | 52.74% | 19.24% | 59.12% |
Capital Expenditures | -115.97 | -87.83 | -74.22 | -13.65 | -40.65 | -152.03 |
Sale of Property, Plant & Equipment | 0.51 | 0.51 | 0.1 | 0 | 0.14 | 0 |
Investment in Securities | 85.72 | 46.75 | -263.83 | -1,301 | 48 | -14.43 |
Other Investing Activities | 21.82 | 22.26 | 41.03 | 4.73 | 2.05 | 2.32 |
Investing Cash Flow | -7.92 | -18.32 | -296.92 | -1,310 | 9.53 | -164.14 |
Long-Term Debt Repaid | - | -1.52 | -1.52 | -2.34 | -2.92 | - |
Net Debt Issued (Repaid) | -1.52 | -1.52 | -1.52 | -2.34 | -2.92 | - |
Issuance of Common Stock | - | - | - | 995.48 | - | 225.66 |
Common Dividends Paid | -176.19 | -176.19 | -136.04 | - | -3.44 | -30.95 |
Other Financing Activities | -0.01 | - | - | -20.3 | -3.03 | -6.32 |
Financing Cash Flow | -177.72 | -177.71 | -137.56 | 972.84 | -9.39 | 188.39 |
Foreign Exchange Rate Adjustments | -0.07 | -0.05 | 0 | - | - | 0.24 |
Net Cash Flow | 106.18 | 79.19 | -177.24 | -84.32 | 165.47 | 163.15 |
Free Cash Flow | 175.92 | 187.42 | 183.02 | 238.87 | 124.67 | -13.38 |
Free Cash Flow Growth | -5.94% | 2.41% | -23.38% | 91.60% | - | - |
Free Cash Flow Margin | 11.19% | 12.13% | 13.88% | 23.13% | 14.56% | -2.30% |
Free Cash Flow Per Share | 0.43 | 0.47 | 0.45 | 0.68 | 0.37 | -0.04 |
Cash Income Tax Paid | 193.68 | 190.65 | 162.07 | 127.8 | 77.47 | 58.49 |
Levered Free Cash Flow | -177.01 | 104.94 | 131.69 | 180.69 | 59.89 | -30.47 |
Unlevered Free Cash Flow | -176.97 | 104.99 | 131.77 | 180.85 | 60.16 | -30.13 |
Change in Working Capital | -33.82 | -33.82 | -31.76 | 16.73 | -13.99 | 6.71 |